The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is continuing
to disrupt personal lives, global healthcare systems, and economies. Hence, there is an …

The emergence of SARS-CoV-2 variants that are more resistant to antibody-mediated
neutralization pose a new hurdle in combating the COVID-19 pandemic. Although vaccines based …

Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not
protect against future novel coronavirus outbreaks, emphasizing the need for more broadly …

Protein nanoparticle scaffolds are increasingly used in next-generation vaccine designs,
and several have established records of clinical safety and efficacy. Yet the rules for how …

Delineating the origins and properties of antibodies elicited by SARS-CoV-2 infection and
vaccination is critical for understanding their benefits and potential shortcomings. Therefore, …

Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2)
are urgently needed. Monoclonal antibodies have shown promising results in patients. …

The enormous sequence diversity between human immunodeficiency virus type 1 (HIV-1)
strains poses a major roadblock for generating a broadly protective vaccine. Many …

Determining how antibodies interact with the spike (S) protein of the SARS-CoV-2 virus is
critical for combating COVID-19. Structural studies typically employ simplified, truncated …

Recombinant native-like HIV-1 envelope glycoprotein (Env) trimers are used in candidate
vaccines aimed at inducing broadly neutralizing antibodies. While state-of-the-art SOSIP or …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
poses continuous challenges in combating the virus. Here, we describe vaccination …